Charles Francis

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi request reprint Ultrasound-enhanced thrombolysis
    C W Francis
    Vascular Medicine Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Echocardiography 18:239-46. 2001
  2. ncbi request reprint Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients
    Charles W Francis
    Department of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    N Engl J Med 356:1438-44. 2007
  3. doi request reprint Prevention of VTE in patients having major orthopedic surgery
    Charles W Francis
    University of Rochester Medical Center, Rochester, NY 14642, USA
    J Thromb Thrombolysis 35:359-67. 2013
  4. ncbi request reprint Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement
    Charles W Francis
    Department of Medicine, University of Rochester, Rochester, NY, USA
    N Engl J Med 349:1703-12. 2003
  5. ncbi request reprint Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation
    C W Francis
    Hematology Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Curr Pharm Des 11:3931-41. 2005
  6. ncbi request reprint Ximelagatran: a new oral anticoagulant
    Charles W Francis
    Hematology Oncology Unit, School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Box 610, Rochester, NY, USA
    Best Pract Res Clin Haematol 17:139-52. 2004
  7. ncbi request reprint Factor XIII polymorphisms and venous thromboembolism
    Charles W Francis
    Vascular Medicine Unit, University of Rochester School of Medicine and Dentistry, NY, USA
    Arch Pathol Lab Med 126:1391-3. 2002
  8. ncbi request reprint Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial
    Charles W Francis
    University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Ann Intern Med 137:648-55. 2002
  9. pmc Prevention of venous thromboembolism in hospitalized patients with cancer
    Charles W Francis
    Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 27:4874-80. 2009
  10. ncbi request reprint Ultrasound and thrombolysis
    C W Francis
    Department of Medicine, University of Rochester School of Medicine and Dentistry, NY, USA
    Vasc Med 6:181-7. 2001

Research Grants

Detail Information

Publications43

  1. ncbi request reprint Ultrasound-enhanced thrombolysis
    C W Francis
    Vascular Medicine Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Echocardiography 18:239-46. 2001
    ..These studies form the basis for clinical trials investigating the potential of ultrasound as an adjunct to improve thrombolytic therapy...
  2. ncbi request reprint Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients
    Charles W Francis
    Department of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    N Engl J Med 356:1438-44. 2007
  3. doi request reprint Prevention of VTE in patients having major orthopedic surgery
    Charles W Francis
    University of Rochester Medical Center, Rochester, NY 14642, USA
    J Thromb Thrombolysis 35:359-67. 2013
    ..Combination therapy consisting of an antithrombotic agent and mechanical device is probably more effective than either alone. The appropriate use of thromboprophylaxis after MOS results in reduced VTE with acceptable bleeding risks...
  4. ncbi request reprint Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement
    Charles W Francis
    Department of Medicine, University of Rochester, Rochester, NY, USA
    N Engl J Med 349:1703-12. 2003
    ..The purpose of the present study was to determine whether a higher dose of ximelagatran is superior to warfarin...
  5. ncbi request reprint Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation
    C W Francis
    Hematology Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Curr Pharm Des 11:3931-41. 2005
    ..The oral direct thrombin inhibitor, ximelagatran, shows promise in providing simplified, effective therapy for venous thromboembolism and atrial fibrillation...
  6. ncbi request reprint Ximelagatran: a new oral anticoagulant
    Charles W Francis
    Hematology Oncology Unit, School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Box 610, Rochester, NY, USA
    Best Pract Res Clin Haematol 17:139-52. 2004
    ..Ximelagatran may be an alternative oral anticoagulant for patients currently taking vitamin K antagonists...
  7. ncbi request reprint Factor XIII polymorphisms and venous thromboembolism
    Charles W Francis
    Vascular Medicine Unit, University of Rochester School of Medicine and Dentistry, NY, USA
    Arch Pathol Lab Med 126:1391-3. 2002
    ..To review the relationship between factor XIII polymorphisms and venous thromboembolism...
  8. ncbi request reprint Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial
    Charles W Francis
    University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Ann Intern Med 137:648-55. 2002
    ..Ximelagatran, an oral direct thrombin inhibitor, has shown promising efficacy and tolerability in patients undergoing total hip or knee arthroplasty...
  9. pmc Prevention of venous thromboembolism in hospitalized patients with cancer
    Charles W Francis
    Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 27:4874-80. 2009
    ..In conclusion, most patients hospitalized with cancer are at high risk of venous thromboembolism, and thromboprophylaxis should be provided in the absence of active bleeding or a high bleeding risk...
  10. ncbi request reprint Ultrasound and thrombolysis
    C W Francis
    Department of Medicine, University of Rochester School of Medicine and Dentistry, NY, USA
    Vasc Med 6:181-7. 2001
    ..The use of ultrasound to mechanically disrupt occlusive thrombi or to accelerate enzymatic thrombolysis offers a new approach to treating occlusive thrombotic disease...
  11. ncbi request reprint Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation
    J T Horan
    Hematology Unit, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Semin Thromb Hemost 27:657-66. 2001
    ..Serial monitoring of soluble fibrin or D-dimer assays may be of value in evaluating the response to therapy and possibly in identifying at-risk patients...
  12. ncbi request reprint Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, New York, USA
    Cancer 104:2822-9. 2005
    ..The incidence of venous thromboembolism (VTE) is increased in cancer, but little information is available about risk factors in cancer patients on chemotherapy...
  13. ncbi request reprint Plasminogen activator inhibitor-1 levels and polymorphisms
    Charles W Francis
    Vascular Medicine Unit, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Arch Pathol Lab Med 126:1401-4. 2002
    ..To review the published evidence of a relationship between levels of plasminogen activator inhibitor-1 (PAI-1) or the 4G/5G polymorphism of the PAI-1 gene and the occurrence of venous thromboembolic disease...
  14. doi request reprint Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital
    Makiko Ban-Hoefen
    Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
    Thromb Res 124:189-92. 2009
    ..The diagnosis depends on a combination of both the clinical presentation and laboratory detection of an appropriate antibody...
  15. pmc Development and validation of a predictive model for chemotherapy-associated thrombosis
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, NY, USA
    Blood 111:4902-7. 2008
    ..5 months (C-statistic = 0.7 for both cohorts). This model can identify patients with a nearly 7% short-term risk of symptomatic VTE and may be used to select cancer outpatients for studies of thromboprophylaxis...
  16. ncbi request reprint Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, New York 14642, USA
    Cancer 110:2339-46. 2007
    ..In the current study, the frequency, risk factors, and trends associated with VTE were examined among hospitalized cancer patients...
  17. ncbi request reprint A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications
    Nicole M Kuderer
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
    Cancer 110:1149-61. 2007
    ....
  18. ncbi request reprint Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer
    Alok A Khorana
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York 14642, USA
    Clin Cancer Res 13:2870-5. 2007
    ..We correlated TF expression with vascular endothelial growth factor (VEGF) expression, microvessel density, and venous thromboembolism in resected pancreatic cancer...
  19. pmc Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer
    Alok A Khorana
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York, USA
    Arch Intern Med 168:2377-81. 2008
    ..Anemia is frequent in patients with cancer, but there are concerns regarding treatment with erythropoiesis-stimulating agents. Blood transfusions are commonly used as an alternative, but with little data regarding outcomes...
  20. ncbi request reprint Endothelial cell activation by IL-1beta in the presence of fibrinogen requires alphavbeta3
    Abha Sahni
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Arterioscler Thromb Vasc Biol 25:2222-7. 2005
    ..The purpose of this study was to investigate the receptor requirements for enhanced IL-1beta-induced secretion of nitric oxide (NO) by endothelial cells (ECs) in the presence of fibrinogen...
  21. ncbi request reprint Thromboembolism in hospitalized neutropenic cancer patients
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 24:484-90. 2006
    ..We investigated venous and arterial thromboembolism and associated outcomes in hospitalized cancer patients actively receiving therapy, as identified by neutropenia...
  22. doi request reprint Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study
    Jorge L Yao
    Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA jorge
    Cancer Invest 27:430-4. 2009
    ..001). Our findings reinforce the link between angiogenesis and TF expression in PCa. We suggest further exploration of TF-mediated pathways leading to increased tumor aggressiveness in PCa, and the possible use of anti-TF agents in PCa...
  23. ncbi request reprint Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight
    Alok A Khorana
    James P Wilmot Cancer Center and Hematology Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY14642, USA
    Arterioscler Thromb Vasc Biol 23:2110-5. 2003
    ..Tumors depend on an expanding vasculature, and heparins may affect vessel growth and function. We investigated the effect of heparins differing in Mr on selected endothelial cell properties...
  24. pmc FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis
    Abha Sahni
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Blood 107:126-31. 2006
    ..These results demonstrate that binding of FGF-2 to fibrin(ogen) mediated by the 5-residue FGF-2-fibrin(ogen) interactive site is required for augmented angiogenesis...
  25. ncbi request reprint Atherosclerotic risk genotypes and recurrent coronary events after myocardial infarction
    Arthur J Moss
    Cardiology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Am J Cardiol 96:177-82. 2005
    ....
  26. ncbi request reprint Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3
    Abha Sahni
    Hematology Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Rochester, NY, USA
    Blood 104:3635-41. 2004
    ..We conclude that fibrinogen binding of FGF-2 enhances EC proliferation through the coordinated effects of colocalized alpha(v)beta(3) and FGFR1...
  27. ncbi request reprint Interleukin-1beta but not IL-1alpha binds to fibrinogen and fibrin and has enhanced activity in the bound form
    Abha Sahni
    Department of Medicine, PO Box 610, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
    Blood 104:409-14. 2004
    ..We conclude that IL-1beta binds with high affinity to fibrin(ogen) and demonstrates increased activity in the bound form...
  28. ncbi request reprint Venous thrombosis and stenosis after implantation of pacemakers and defibrillators
    Grzegorz Rozmus
    Cardiology Unit of the Department of Medicine, University of Rochester Medical Center, Strong Memorial Hospital, 601 Elmwood Ave, Box 679, Rochester, NY, 14642, USA
    J Interv Card Electrophysiol 13:9-19. 2005
    ..Anticoagulant therapy (for other reasons than pacemaker lead) seemed to have protective antithrombotic effect...
  29. ncbi request reprint Identification of a binding site on human FGF-2 for fibrinogen
    Hu Peng
    Department of Medicine, Hematology Oncology Unit, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Rochester, NY 14642, USA
    Blood 103:2114-20. 2004
    ..3 nM and 8.6 nM, respectively, compared with 1.3 nM for wild-type FGF-2. We conclude that these 5 residues define a high-affinity binding site in FGF-2 for fibrinogen...
  30. ncbi request reprint Fibrinogen regulates the expression of inflammatory chemokines through NF-kappaB activation of endothelial cells
    Min Guo
    Hematology Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Thromb Haemost 92:858-66. 2004
    ..From our findings, we conclude that fibrinogen regulates NF-kappaB activation and expression of inflammatory chemokines in endothelial cells and may be involved in mediating inflammatory processes...
  31. pmc Foxp3 regulates megakaryopoiesis and platelet function
    Jamie J Bernard
    Department of Environmental Medicine, University of Rochester, Rochester, NY 14642, USA
    Arterioscler Thromb Vasc Biol 29:1874-82. 2009
    ..Scurfy mice and some humans with IPEX are also thrombocytopenic. The purpose of this study was to determine whether the absence of functional Foxp3 leads to defects in megakaryocytes and platelets...
  32. pmc Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles
    Denise M Ray
    University of Rochester Medical Center, Environmental Medicine, Rochester, New York 14642, USA
    Thromb Haemost 99:86-95. 2008
    ....
  33. pmc Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy
    Gregory C Connolly
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, NY, USA
    Thromb Res 126:113-8. 2010
    ..Leukocytosis has been associated with thrombosis and mortality in cancer patients. We explored the association of leukocytosis with venous thromboembolism (VTE) and early mortality in cancer patients initiating chemotherapy...
  34. ncbi request reprint NF-kappaB activation suppresses host cell apoptosis during Rickettsia rickettsii infection via regulatory effects on intracellular localization or levels of apoptogenic and anti-apoptotic proteins
    Suresh G Joshi
    Hemostasis and Thrombosis Program, Hematology Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, P O Box 610, 601 Elmwood Avenue, Rochester, NY 14642, USA
    FEMS Microbiol Lett 234:333-41. 2004
    ....
  35. ncbi request reprint Direct thrombin inhibitors
    Karen L Kaplan
    Hematology Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Semin Hematol 39:187-96. 2002
    ..The chemical structure, kinetics of thrombin inhibition, pharmacokinetics, and clinical use of each of these agents are discussed...
  36. ncbi request reprint American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
    Gary H Lyman
    Duke University Medical Center, University of Rochester Medical Center, Rochester, USA
    J Clin Oncol 25:5490-505. 2007
    ..To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer...
  37. ncbi request reprint Venous thromboembolism in patients with diffuse large B-cell lymphoma
    Rami S Komrokji
    Department of Medicine, University of Cincinnati and Cincinnati Veterans Administration Medical Center, Cincinnati, OH 45267 0501, USA
    Leuk Lymphoma 47:1029-33. 2006
    ..2 years (95% CI 1.8 - 8.6) for those without VTE (P = 0.038). We conclude that VTE is a frequent complication of DLBCL that occurs particularly at diagnosis and during initial therapy, and it is associated with a worse prognosis...
  38. ncbi request reprint Randomized prospective study comparing routine versus selective use of sonography of the complete calf in patients with suspected deep venous thrombosis
    Ronald H Gottlieb
    Department of Radiology, University of Rochester Medical Center, 601 Elmwood Ave, Box 648, Rochester, NY 14642, USA
    AJR Am J Roentgenol 180:241-5. 2003
    ..We compared patient outcomes using two protocols: one routinely and the other selectively evaluating the calves completely during sonographic assessment of the lower extremities in patients with suspected deep venous thrombosis...
  39. pmc 15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes
    Jamie J O'Brien
    Department of Environmental Medicine and the Lung Biology and Disease Program, University of Rochester, NY, USA
    Blood 112:4051-60. 2008
    ....
  40. ncbi request reprint Ultrasound enhancement of fibrinolysis at frequencies of 27 to 100 kHz
    Valentina Suchkova
    Vascular Medicine Unit, Department of Medicine, Rochester Center for Biomedical Ultrasound, Rochester, NY 14642, USA
    Ultrasound Med Biol 28:377-82. 2002
    ..We conclude that US in the range of 27 to 100 kHz is effective in accelerating fibrinolysis at intensities and pulsing conditions that minimize the probability of heating and cavitation in clinical applications...
  41. ncbi request reprint Ultrasound improves tissue perfusion in ischemic tissue through a nitric oxide dependent mechanism
    Valentina N Suchkova
    Hematology Oncology Unit, Department of Medicine, University of Rochester Medical Center, NY 14642, USA
    Thromb Haemost 88:865-70. 2002
    ..We conclude that the application of 40 kHz at low intensity improves perfusion and reverses acidosis in acutely ischemic muscle through a nitric oxide dependent mechanism...
  42. ncbi request reprint Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty
    Clifford W Colwell
    Orthopaedic Surgery, Scripps Clinic, 11025 North Torrey Pines Road, Suite 140, La Jolla, CA 92037, USA
    J Bone Joint Surg Am 87:2169-77. 2005
    ....
  43. ncbi request reprint Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial
    Jean Noel Fiessinger
    Department of Vascular Medicine, Hopital Europeen Georges Pompidou, Paris, France
    JAMA 293:681-9. 2005
    ..Ximelagatran, an oral direct thrombin inhibitor with a rapid onset of action and predictable antithrombotic effect, has the potential to be a simple therapeutic alternative to current standard treatment of acute venous thromboembolism...

Research Grants5

  1. GRADUATE TRAINING HEMATOLOGY RESEARCH
    Charles Francis; Fiscal Year: 2007
    ..The program will be directed by Dr. Charles Francis, Director of the Program in Thrombosis and Hemostasis and by a Co-director, Dr...
  2. Venous Thrombosis in Cancer Outpatients: Prevention and Role of Tissue Factor
    Charles W Francis; Fiscal Year: 2010
    ..We will also do studies to determine if certain abnormalities in the blood clotting system can help predict this problem. ..